Literature DB >> 9559786

Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

S Bantia1, A A Ghate, S L Ananth, Y S Babu, G M Air, G M Walsh.   

Abstract

Influenza neuraminidase (NA) plays an important role in viral replication, and characterization of viruses resistant to NA inhibitors will help elucidate the role of active-site residues. This information will assist in designing better inhibitors targeted to essential active-site residues that cannot generate drug-resistant mutations. In the present study we used the benzoic acid-based inhibitor BCX-140 to select and characterize resistant viruses. BCX-140 binds to the NA active site in an orientation that is opposite that of a sialic acid-based compound, 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (GANA). Thus, the guanidino group of BCX-140 binds to Glu-276, whereas in GANA the guanidino group binds to Glu-119. We passaged influenza A/Singapore/1/57 (H2N2) in Madin-Darby canine kidney cells in the presence of BCX-140, and virus resistant to this inhibitor was selected after six passages. The NA of this mutant was still sensitive to inhibition by BCX-140. However, the mutant virus was resistant to BCX-140 in plaque and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Sequence analysis of hemagglutinin (HA) and NA genes revealed changes in both, although none were in the active site of the NA. Depending on the method of selection of the resistant virus, two types of changes associated with the sialic acid binding site were seen in the HA. One is a change in HA1 of Ala-133 to Thr, a residue close to the binding site, while the other change was Arg-132 of HA1 to Gln, which in HA1 of serotype H3 is a sialic acid contact (Asn-137). Binding studies revealed that both types of resistant viruses had reduced receptor binding affinity compared to that of the wild type. Thus, resistance to BCX-140 was generated by modifying the HA. NA active-site residue 276 may be essential for activity, and thus, it cannot be changed to generate resistance. However, drug-induced changes in the HA can result in a virus that is less dependent on NA activity for growth in cells and, hence, resistant to NA inhibitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559786      PMCID: PMC105545          DOI: 10.1128/AAC.42.4.801

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Authors:  J L McKimm-Breschkin; T J Blick; A Sahasrabudhe; T Tiong; D Marshall; G J Hart; R C Bethell; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

Authors:  M Potier; L Mameli; M Bélisle; L Dallaire; S B Melançon
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

3.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.

Authors:  P Palese; K Tobita; M Ueda; R W Compans
Journal:  Virology       Date:  1974-10       Impact factor: 3.616

4.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; R Bethell; G J Hart; K G Murti; C R Penn; R G Webster
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.

Authors:  K A Staschke; J M Colacino; A J Baxter; G M Air; A Bansal; W J Hornback; J E Munroe; W G Laver
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

6.  A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.

Authors:  M J Jedrzejas; S Singh; W J Brouillette; G M Air; M Luo
Journal:  Proteins       Date:  1995-10

7.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.

Authors:  I A Wilson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

8.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase.

Authors:  P M Colman; J N Varghese; W G Laver
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

9.  Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase.

Authors:  G M Air; M C Els; L E Brown; W G Laver; R G Webster
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

10.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  14 in total

1.  Mutation signature in neuraminidase gene of avian influenza H9N2/G1 in Egypt.

Authors:  Zienab Mosaad; Abdelsatar Arafa; Hussein A Hussein; Mohamed A Shalaby
Journal:  Virusdisease       Date:  2017-05-23

2.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

3.  How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.

Authors:  Andreas Handel; Victoria Akin; Sergei S Pilyugin; Veronika Zarnitsyna; Rustom Antia
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

4.  CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Authors:  Makoto Yamashita; Takanori Tomozawa; Masayo Kakuta; Akane Tokumitsu; Hatsumi Nasu; Shuku Kubo
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Antiviral strategies for pandemic and seasonal influenza.

Authors:  Maria Hedlund; Jeffrey L Larson; Fang Fang
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

Review 6.  Influenza neuraminidase.

Authors:  Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2011-11-16       Impact factor: 4.380

7.  Compensatory evolution of net-charge in influenza A virus hemagglutinin.

Authors:  Yuki Kobayashi; Yoshiyuki Suzuki
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240

8.  Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.

Authors:  Shelly Gulati; David F Smith; Gillian M Air
Journal:  Virol J       Date:  2009-02-14       Impact factor: 4.099

9.  Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.

Authors:  Natalia A Ilyushina; Elena A Govorkova; Thomas E Gray; Nicolai V Bovin; Robert G Webster
Journal:  PLoS Pathog       Date:  2008-04-11       Impact factor: 6.823

10.  Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities.

Authors:  Donald J Benton; Stephen R Martin; Stephen A Wharton; John W McCauley
Journal:  J Biol Chem       Date:  2015-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.